Testing Finerenone and Empagliflozin Together for Hospitalized Heart Failure Patients
Tests two heart medicines together, compared with usual care, in adults hospitalized with heart failure.
Plain-language title generated from the registry record
Registry title: A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Key facts
- Where
- Edmonton, Greater Sudbury, London, Montreal, North York, Sherbrooke, Surrey, and Toronto, CanadaSee the 10 sites
- Phase
- Phase 3
Where in Canada
- CON-11011, Edmonton, ABEdmonton, CanadaTaking people
- CON-11016, Sudbury, ONGreater Sudbury, CanadaTaking people
- CON-11010, London, ONLondon, CanadaTaking people
- CON-11026, Montreal, QuebecMontreal, CanadaTaking people
- North YorkNorth York, CanadaTaking people
- SherbrookeSherbrooke, CanadaTaking people
- SurreySurrey, CanadaTaking people
- CON-11001, Toronto, ONToronto, CanadaTaking people
- CON-11008, Toronto, ONToronto, CanadaTaking people
- CON-11019, Toronto, ONToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Colorado Prevention Center
- Trial code
- NCT06024746
- Record updated
- 10 September 2026
- Original description
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.Read full original descriptionShow less
Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Inclusion: Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations; Age ≥18 years or legal age of majority if >18 years in the participant's country of residence; Current hospitalization or recently discharged with the primary diagnosis of heart failure; Heart failure signs and symptoms at the time of hospital admission; Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg/mL or B-type natriuretic peptide (BNP) ≥125 pg/mL according to the local lab for patients in sinus rhythm; or elevated NTproBNP ≥1500 pg/mL or BNP ≥375 pg/mL for patients with atrial fibrillation (AF), measured during the current hospitalization or in the 72 hours prior to hospital admission; Fulfillment of protocol defined stabilization criteria (if randomized during hospitalization); Treatment during the index hospitalization with at least 1 intravenous dose of a loop diuretic (e.g., furosemide, torsemide, bumetanide); Negative pregnancy test and agreement to use adequate contraception during trial (female participants only).
Exclusion: Diagnosis of type 1 diabetes or prior history of diabetic ketoacidosis; Documented prior history of severe hyperkalemia in the setting of MRA use; Treatment with non-steroidal mineralocorticoid receptor antagonist (MRA) or SGLT2i; Prior or planned heart transplant; Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers; Acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days; Hemodynamically significant uncorrected primary cardiac valvular disease as primary cause of heart failure; Cardiomyopathy due to acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction; Probable alternative cause of participant's heart failure symptoms; Known hypersensitivity to the IP (active substance or excipients); Any other condition or therapy which would make the patient unsuitable for this study; Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² and/or potassium >5.0 mmol/L.